Edition:
United Kingdom

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

139.65USD
10 Dec 2018
Change (% chg)

$-1.52 (-1.08%)
Prev Close
$141.17
Open
$140.89
Day's High
$140.89
Day's Low
$136.35
Volume
407,191
Avg. Vol
193,027
52-wk High
$183.96
52-wk Low
$130.15

Chart for

About

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $8,797.71
Shares Outstanding(Mil.): 60.06
Dividend: --
Yield (%): --

Financials

  JAZZ.OQ Industry Sector
P/E (TTM): 22.31 31.13 33.63
EPS (TTM): 6.57 -- --
ROI: 10.38 15.55 15.02
ROE: 20.73 16.92 16.60

U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine.

13 Jul 2018

UPDATE 2-U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

July 13 A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine.

13 Jul 2018

U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug

July 13 A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals Inc to launch a generic version of the medicine.

13 Jul 2018

Earnings vs. Estimates